Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Friday, December 9, 2016

Michael J. Fox Foundation (MJFF) Parkinsons' progress

Look at what can occur when a disease foundation has a strategy and the research to followup that strategy. Our fucking failures of stroke associations can't even copy successful non-profits, they are that fucking bad. And our boards of directors don't seem to know how bad they are. Contact me for help.
View this email as a webpage | Add to your address book | Contact Us
The Michael J. Fox Foundation (MJFF) works with the Parkinson's community every day. They tell us they need better treatments to manage symptoms and side effects -- and most importantly, a cure. Our Foundation is working urgently to deliver all of these.
We are energized when we hear of progress toward these goals. Just this week, an MJFF-funded biotech announced positive Phase I results for a treatment to help the optimal amount of levodopa (the "gold standard" PD therapy) reach the right part of the brain with greater precision. The treatment proved safe and holds potential to help those with advancing disease maintain a higher quality of life.
And earlier this fall, a drug that addresses dyskinesia (involuntary movements often experienced by those taking levodopa long-term) was submitted for FDA approval, propelled by tools we developed to help rate patient benefit and recruit clinical trial volunteers.
These advances speak to the unique approach we at the Foundation take to identifying the most promising ideas in order to yield real scientific solutions. It's a strategy that requires efficient problem-solving, smart risk-taking and critically, your support.
We endeavor only to bring life-changing therapies such as these -- and a treatment that slows or stops Parkinson's in its tracks -- closer to patients' hands.

You are a vital part of this work. Please donate today to help us continue bringing good news to you -- and the estimated 5 million people living with Parkinson's worldwide.

Todd Sherer, PhD

P.S. Our commitment to tangible progress for patients is matched with one to use your donations wisely: 89 cents of every dollar we spend goes directly to our programs to speed breakthroughs in PD research.

No comments:

Post a Comment